Expression of a Dominant Negative Estrogen Receptor Alpha Variant in Transgenic Mice Accelerates Uterine Cancer Induced by the Potent Estrogen Diethylstilbestrol

Overview

Journal Reprod Toxicol

Specialties Reproductive Medicine
Toxicology

Date 2012 Sep 20

PMID 22989549

Citations 4

Authors

Vicki L Davis

Retha R Newbold

John F Couse

Sheri L Rea

Katie M Gallagher

Katherine J Hamilton

Eugenia H Goulding

Wendy Jefferson

E M Eddy

Bill C Bullock

Kenneth S Korach

Affiliations

Soon will be listed here.

Abstract

ERΔ3 transgenic mice expressing a dominant negative estrogen receptor α (ERα) variant lacking the second zinc finger in the DNA binding domain were developed to examine its potential to inhibit estrogen action in vivo. To investigate if ERΔ3 expression influences uterine carcinogenesis, ERΔ3 transgenic mice were exposed to diethylstilbestrol (DES) on post-natal days 1-5. Neonatal DES treatment induced uterine adenocarcinomas in 81% of 8-month-old ERΔ3 mice compared to 49% of wild-type females (p<0.016). ERΔ3 did not inhibit the expression of the estrogen-responsive progesterone receptor and lactoferrin genes in the presence of ERα or modify their expression in ERα knockout (αERKO) mice. Higher circulating 17β-estradiol levels and non-classical signaling by ERΔ3 may be related to the earlier incidence of uterine cancer. These findings indicate that expression of this ERα variant can influence determining events in uterine cancer development and its natural occurrence in the human uterus would unlikely be protective.

Citing Articles

Developmental exposure to phytoestrogens found in soy: New findings and clinical implications.

Suen A, Kenan A, Williams C Biochem Pharmacol. 2021; 195:114848.

PMID: 34801523 PMC: 8712417. DOI: 10.1016/j.bcp.2021.114848.

Subcellular dynamics of estrogen-related receptors involved in transrepression through interactions with scaffold attachment factor B1.

Tanida T, Matsuda K, Uemura T, Yamaguchi T, Hashimoto T, Kawata M Histochem Cell Biol. 2021; 156(3):239-251.

PMID: 34129097 DOI: 10.1007/s00418-021-01998-7.

SIX1 Regulates Aberrant Endometrial Epithelial Cell Differentiation and Cancer Latency Following Developmental Estrogenic Chemical Exposure.

Suen A, Jefferson W, Wood C, Williams C Mol Cancer Res. 2019; 17(12):2369-2382.

PMID: 31597742 PMC: 6891210. DOI: 10.1158/1541-7786.MCR-19-0475.

Inhibition of Neu-induced mammary carcinogenesis in transgenic mice expressing ERΔ3, a dominant negative estrogen receptor α variant.

Davis V, Shaikh F, Gallagher K, Villegas M, Rea S, Cline J Horm Cancer. 2012; 3(5-6):227-39.

PMID: 22968785 PMC: 10358148. DOI: 10.1007/s12672-012-0122-x.

References

Couse J, Curtis S, Washburn T, Lindzey J, Golding T, Lubahn D . Analysis of transcription and estrogen insensitivity in the female mouse after targeted disruption of the estrogen receptor gene. Mol Endocrinol. 1995; 9(11):1441-54. DOI: 10.1210/mend.9.11.8584021. View

Safe S, Kim K, Kim K . Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. J Mol Endocrinol. 2008; 41(5):263-75. PMC: 2582054. DOI: 10.1677/JME-08-0103. View

Lubahn D, Moyer J, Golding T, Couse J, Korach K, SMITHIES O . Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci U S A. 1993; 90(23):11162-6. PMC: 47942. DOI: 10.1073/pnas.90.23.11162. View

Couse J, Davis V, Hanson R, Jefferson W, McLachlan J, Bullock B . Accelerated onset of uterine tumors in transgenic mice with aberrant expression of the estrogen receptor after neonatal exposure to diethylstilbestrol. Mol Carcinog. 1997; 19(4):236-42. DOI: 10.1002/(sici)1098-2744(199708)19:4<236::aid-mc4>3.0.co;2-a. View

Couse J, Dixon D, Yates M, Moore A, Ma L, Maas R . Estrogen receptor-alpha knockout mice exhibit resistance to the developmental effects of neonatal diethylstilbestrol exposure on the female reproductive tract. Dev Biol. 2002; 238(2):224-38. DOI: 10.1006/dbio.2001.0413. View

Davis V, Chan C, Schoen T, Couse J, Chader G, Korach K . An estrogen receptor repressor induces cataract formation in transgenic mice. Proc Natl Acad Sci U S A. 2002; 99(14):9427-32. PMC: 123157. DOI: 10.1073/pnas.132247999. View

Curtis S, Washburn T, Sewall C, DiAugustine R, Lindzey J, Couse J . Physiological coupling of growth factor and steroid receptor signaling pathways: estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor. Proc Natl Acad Sci U S A. 1996; 93(22):12626-30. PMC: 38043. DOI: 10.1073/pnas.93.22.12626. View

Marshburn P, Zhang J, Bahrani-Mostafavi Z, Mostafavi B, Marroum M, Mougeot J . Estrogen receptor-alpha messenger RNA variants that lack exon 5 or exon 7 are coexpressed with wild-type form in human endometrium during all phases of the menstrual cycle. Am J Obstet Gynecol. 2004; 191(2):626-33. DOI: 10.1016/j.ajog.2004.05.082. View

Tinelli A, Vergara D, Martignago R, Leo G, Malvasi A, Tinelli R . Hormonal carcinogenesis and socio-biological development factors in endometrial cancer: a clinical review. Acta Obstet Gynecol Scand. 2008; 87(11):1101-13. DOI: 10.1080/00016340802160079. View

10.

Kumar V, Chambon P . The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell. 1988; 55(1):145-56. DOI: 10.1016/0092-8674(88)90017-7. View

11.

Saffell J, Williams E, Mason I, Walsh F, Doherty P . Expression of a dominant negative FGF receptor inhibits axonal growth and FGF receptor phosphorylation stimulated by CAMs. Neuron. 1997; 18(2):231-42. DOI: 10.1016/s0896-6273(00)80264-0. View

12.

Bollig A, Miksicek R . An estrogen receptor-alpha splicing variant mediates both positive and negative effects on gene transcription. Mol Endocrinol. 2000; 14(5):634-49. DOI: 10.1210/mend.14.5.0460. View

13.

Horwitz R, Viscoli C, Merino M, Brennan T, Flannery J, Robboy S . Clear cell adenocarcinoma of the vagina and cervix: incidence, undetected disease, and diethylstilbestrol. J Clin Epidemiol. 1988; 41(6):593-7. DOI: 10.1016/0895-4356(88)90064-9. View

14.

Sunaga S, Maki K, Lagasse E, Blanco J, Ozato K, Miyazaki J . Myeloid differentiation is impaired in transgenic mice with targeted expression of a dominant negative form of retinoid X receptor beta. Br J Haematol. 1997; 96(1):19-30. DOI: 10.1046/j.1365-2141.1997.8692483.x. View

15.

Moriarty K, Kim K, Bender J . Minireview: estrogen receptor-mediated rapid signaling. Endocrinology. 2006; 147(12):5557-63. DOI: 10.1210/en.2006-0729. View

16.

Newbold R, McLachlan J . Transplacental hormonal carcinogenesis: diethylstilbestrol as an example. Prog Clin Biol Res. 1996; 394:131-47. View

17.

McLachlan J, Newbold R . Cellular and molecular mechanisms of cancers of the uterus in animals. Prog Clin Biol Res. 1996; 394:175-82. View

18.

Holt L, Herbst A . DES-related female genital changes. Semin Oncol. 1982; 9(3):341-8. View

19.

Petz L, Ziegler Y, Schultz J, Nardulli A . Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site. Mol Endocrinol. 2003; 18(3):521-32. DOI: 10.1210/me.2003-0105. View

20.

Taketo M, Schroeder A, Mobraaten L, Gunning K, Hanten G, Fox R . FVB/N: an inbred mouse strain preferable for transgenic analyses. Proc Natl Acad Sci U S A. 1991; 88(6):2065-9. PMC: 51169. DOI: 10.1073/pnas.88.6.2065. View